Stroke and spinal cord damage are medical disorders that can cause death or lifelong disability. Credit: Albina Gavrilovic / Shutterstock.com.

Scientists from the universities of Birmingham and Sheffield have partnered with NLC Health Ventures for the launch of Midland Pharmaceuticals to focus on the development of a new therapeutic for spinal cord injury and cerebrovascular disease, including stroke.

Dr Peter Suzdak is serving as the CEO of Midland.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The newly launched company will advance the clinical development of MLP-1236, a dual inhibitor of MMP-9 and MMP-12 enzymes that are associated with the inflammatory process following injury to the central nervous system.

MLP-1236 has concluded Phase I and Phase IIa clinical trials, demonstrating safety and tolerability.

The therapeutic has shown promise in preclinical models, effectively reversing pathologies associated with spinal cord injury and reducing brain tissue death in stroke models.

See Also:

Following fundraising efforts, Midland Pharmaceuticals plans to initiate a Phase IIb clinical trial for spinal cord injury patients and a subsequent trial for stroke.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Suzdak said: “The loss of sensory and motor function that occurs following spinal cord injury and stroke represents a major unmet medical need.

“Current therapies offer only modest symptomatic benefits to these patients but do not treat the underlying neuronal damage that occurs. Inhibition of MMP-9 and -12 with MLP-1236 has the possibility of transforming the way these patients are treated.”

Stroke and spinal cord damage are medical disorders that can cause death or lifelong disability. There is a need for new, more potent therapeutic approaches since current medicines are either ineffective or just provide symptomatic alleviation.

Researchers from both universities are experienced in drug discovery and clinical development.